Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorMontefiore Medical Center
About this trial
The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP
Eligibility criteria
Qualifiers
Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
Patients aged 18 years and older.
Patient willing to provide consent to be a participant in the study.
Patients with insurance that allows Dupilumab coverage or Dupilumab coverage obtained through "Dupixent MyWay Program"
Disqualifiers
Age under 18
Suspected or diagnosed allergic fungal rhinosinusitis.
Suspected or diagnosed cystic fibrosis.
Dupilumab coverage denied through insurance or "Dupixent MyWay Program"
Trial design
Treatments tested in this trial
- Dupilumab
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov